Founder, Chairman & CEO
Mark C. McKenna is the founder, chairman, and CEO of Mirador Therapeutics and a renowned biotech entrepreneur known for his leadership and innovation in the biotech industry.
As Chairman, President, and CEO of Prometheus Biosciences (Nasdaq: RXDX) from 2019 to 2023, he led the company to a $10.8 billion acquisition by Merck. Under his guidance, Prometheus raised over $1 billion and pioneered developing precision therapeutics for immune-mediated diseases.
Previously, Mr. McKenna was a corporate officer at Bausch Health and President of Salix Pharmaceuticals. Mr. McKenna began his career at Johnson & Johnson and now serves as Chairman of Apogee Therapeutics (Nasdaq: APGE) and as a board member of Spyre Therapeutics (Nasdaq: SYRE). He was named Ernst & Young Entrepreneur of the Year in 2023.
He holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University.